HARVONI Drug Patent Profile

Which patents cover Harvoni, and what generic alternatives are available?

Harvoni is a drug marketed by Gilead Sciences Inc and is included in two NDAs. There are seventeen patents protecting this drug.

This drug has five hundred and sixty-five patent family members in fifty countries.

The generic ingredient in HARVONI is ledipasvir; sofosbuvir. There is one drug master file entry for this compound. Two suppliers are listed for this compound. Additional details are available on the ledipasvir; sofosbuvir profile page.

DrugPatentWatch^® Generic Entry Outlook for Harvoni

Harvoni was eligible for patent challenges on October 10, 2018.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be November 12, 2030. This may change due to patent challenges or generic licensing.

There have been four patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for HARVONI

International Patents:	565
US Patents:	17
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	36
Drug Prices:	Drug price information for HARVONI
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for HARVONI
What excipients (inactive ingredients) are in HARVONI?	HARVONI excipients list
DailyMed Link:	HARVONI at DailyMed

See drug prices for HARVONI

See drug sales revenues for HARVONI

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for HARVONI

Constraining patent/regulatory exclusivity:

8,088,368*PED

NDA:

212477

Dosage:

PELLETS;ORAL

Constraining patent/regulatory exclusivity:

8,088,368*PED

NDA:

205834

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for HARVONI

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Mansoura University	Phase 3
Cairo University	Phase 2/Phase 3
University of Maryland, College Park	Early Phase 1

See all HARVONI clinical trials

Pharmacology for HARVONI

Drug Class	Hepatitis C Virus NS5A Inhibitor Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor
Mechanism of Action	Breast Cancer Resistance Protein Inhibitors P-Glycoprotein Inhibitors RNA Replicase Inhibitors

US Patents and Regulatory Information for HARVONI

HARVONI is protected by seventeen US patents and four FDA Regulatory Exclusivities.

This potential generic entry date is based on patent 8,088,368.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Gilead Sciences Inc	HARVONI	ledipasvir; sofosbuvir	TABLET;ORAL	205834-001	Oct 10, 2014		RX	Yes	Yes	9,284,342*PED				Y
Gilead Sciences Inc	HARVONI	ledipasvir; sofosbuvir	TABLET;ORAL	205834-002	Aug 28, 2019		RX	Yes	No	8,334,270*PED				Y
Gilead Sciences Inc	HARVONI	ledipasvir; sofosbuvir	PELLETS;ORAL	212477-002	Aug 28, 2019		RX	Yes	Yes	9,393,256*PED				Y
Gilead Sciences Inc	HARVONI	ledipasvir; sofosbuvir	TABLET;ORAL	205834-002	Aug 28, 2019		RX	Yes	No	8,735,372*PED				Y
Gilead Sciences Inc	HARVONI	ledipasvir; sofosbuvir	TABLET;ORAL	205834-001	Oct 10, 2014		RX	Yes	Yes	8,618,076*PED				Y
Gilead Sciences Inc	HARVONI	ledipasvir; sofosbuvir	TABLET;ORAL	205834-002	Aug 28, 2019		RX	Yes	No	8,618,076*PED				Y
Gilead Sciences Inc	HARVONI	ledipasvir; sofosbuvir	TABLET;ORAL	205834-002	Aug 28, 2019		RX	Yes	No	8,889,159*PED				Y

International Patents for HARVONI

When does loss-of-exclusivity occur for HARVONI?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

African Regional IP Organization (ARIPO)

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Croatia

Cyprus

Denmark

Ecuador

Eurasian Patent Organization

European Patent Office

France

Hong Kong

Hungary

Israel

Japan

Lithuania

Mexico

Montenegro

Netherlands

New Zealand

Norway

Peru

Poland

Portugal

San Marino

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Ukraine

Uruguay

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering HARVONI around the world.

Country	Patent Number	Title	Estimated Expiration
Taiwan	201318627
Finland	C20140055
Netherlands	300796
Spain	2771458
Spain	2551944
Brazil	122014012810
Cyprus	1119896

Supplementary Protection Certificates for HARVONI

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2203462	201440043	Slovenia		PRODUCT NAME: SOFOSBUVIR; NATIONAL AUTHORISATION NUMBER: EU/1/13/894/001-002; DATE OF NATIONAL AUTHORISATION: 20140116; AUTHORITY FOR NATIONAL AUTHORISATION: EU
2203462	132014902310732	Italy		PRODUCT NAME: SOFOSBUVIR(SOVALDI); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/13/894, 20140117
2203462	1491066-5	Sweden		PRODUCT NAME: SOFOSBUVIR; FIRST MARKETING AUTHORIZATION NUMBER SE: EG EU/1/13/894, 2014-01-17
2203462	C300704	Netherlands		PRODUCT NAME: SOVALDI (SOFOSBUVIR); REGISTRATION NO/DATE: EU/1/13/894/001-002 20140117
2430014	631	Finland
2430014	SPC/GB16/008	United Kingdom		PRODUCT NAME: LEDIPASVIR; REGISTERED: UK EU/1/14/958(001-002) 20141118
2203462	C20140035 00135	Estonia		PRODUCT NAME: SOFOSBUVIIR

Harvoni (sofosbuvir/ledipasvir): Market Dynamics and Financial Trajectory

Last updated: April 24, 2026

What is the product and how did it get to market?

Harvoni is a fixed-dose combination of sofosbuvir + ledipasvir used for treatment of chronic hepatitis C virus (HCV) infection. It launched in the U.S. in 2014 under Gilead Sciences. Its commercial arc is dominated by (1) rapid uptake due to high cure rates, (2) subsequent erosion from (3) expanded generic and alternative DAA competition and (4) shrinking treatable populations as diagnosed cases clear or become harder to access.

Key launch and regulatory milestones:

• 2014: U.S. launch year for Harvoni (DAA era scale-up) (source: FDA Drug Approval Package) [1]
• Harvoni remains an anchor in DAA treatment strategies but faces category-wide volume decline as curing reduces new incident demand (category dynamics described in Gilead segment disclosures and public filings) [2], [3]

How has the market demand for Harvoni shifted over time?

Harvoni’s demand followed the classic DAA adoption pattern:

1. Early diffusion (2014-2015): broad clinician adoption for genotype coverage and favorable tolerability.
2. Normalization (2016-2017): peak penetration as formularies and payer protocols tightened around DAAs.
3. Late-stage pressure (2018 onward): lower volumes due to (a) competition from newer DAAs and (b) category demand compression as more eligible patients get treated.

Two structural drivers shaped the long-run curve:

• HCV incidence and prevalence decline among treatable populations in major markets as DAAs cure patients and reduce the pool of chronic carriers over time (discussed through Gilead’s public segment framing around HCV maturation) [2], [3]
• Patent and exclusivity expiry plus generic entry across key geographies reduced net pricing and market share over time (captured in Gilead’s product sales narratives for HCV brands transitioning to a lower-price environment) [2], [3]

What competitive forces pressured Harvoni’s pricing and volume?

Harvoni competed in a crowded direct-acting antiviral landscape. Pressure intensified as:

• Other multi-pill or fixed-dose DAAs achieved similar cure rates across genotypes and expanded indications.
• Payer behavior shifted toward lowest net-cost regimens after competition increased.
• Generic and biosimilar-like substitution dynamics (in effect for DAAs) reduced brand economics faster than early DAA competitors expected.

The result was a financial trajectory characterized by front-loaded sales and sustained decline after peak. Gilead’s reporting on HCV product transitions shows the category moving from growth to maturity and then to erosion, with Harvoni no longer carrying the same revenue lift as in early years (source: Gilead annual reporting) [2], [3].

What does the financial trajectory show?

Harvoni is a component of Gilead’s broader HCV commercial story, and its decline is visible in Gilead’s reported HCV net product sales and its segment communications over time. While exact year-by-year Harvoni-only figures are not consistently separated in all public summaries, Gilead’s consolidated HCV revenue trend captures the same underlying economics: high early peak followed by steady erosion as competition and treatment maturation take hold.

Gilead’s HCV business trend and Harvoni’s role

• 2014-2017: Harvoni helped drive the HCV category’s peak revenue period for Gilead (DAA uptake and broad prescribing) [2], [3]
• 2018 onward: category revenue declines accelerated as competition expanded and pricing normalized [2], [3]
• 2023-2024: HCV is no longer a growth engine; it is managed as a mature portfolio with declining demand and diminishing brand economics (reflected in Gilead’s segment and pipeline positioning after HCV maturation) [2], [3]

Corporate trajectory: margin impact and capital allocation

As HCV revenues declined, Gilead’s operating emphasis shifted toward:

• Oncology and HIV franchises,
• Expanded pipeline monetization strategies,
• Cost discipline tied to lower HCV cash generation (captured in annual reporting and business-overview sections) [2], [3]

This portfolio reallocation matters for Harvoni indirectly: it reduces incentives to sustain premium pricing and raises the importance of lower-cost regimens across payer networks.

How did payer and policy dynamics affect Harvoni’s uptake and later decline?

The DAA market is payer-led once cure rates equalize. Harvoni’s early success relied on:

• Broad formulary acceptance due to high SVR rates and lower side-effect burden (clinical outcomes drove coverage decisions tied to cure endpoints) [1]

Later decline followed typical payer tightening:

• Net price pressure as competing DAAs and generics gained access.
• Utilization management through step edits and restriction to specific populations as eligibility criteria tightened.
• Preference for regimens with the lowest total net cost once clinical differentiation narrowed.

Where did Harvoni face the sharpest erosion?

Erosion is strongest in markets where:

• exclusivity ends,
• national procurement drives tender-based pricing,
• and generic substitution is most active.

Gilead’s global reporting frames HCV as shifting from brand leadership into maturity with continued decline pressures from competition and pricing normalization (source: annual reporting commentary on HCV product sales dynamics) [2], [3].

What is the investment-relevant take on Harvoni’s cash curve?

For an investor or R&D strategist, Harvoni’s financial trajectory has three actionable implications:

1. DAA category economics are front-loaded
   Competitive entry and payer net pricing compress revenue faster once multiple highly effective regimens exist. Harvoni fits that pattern: peak adoption after launch followed by long decline.

2. Brand durability declines when clinical differentiation collapses
   When cure rates converge, payer selection shifts to net price and access. Harvoni’s long-run value depends on how long it held formulary preference amid generics and alternatives (reflected in Gilead’s HCV revenue maturation language) [2], [3].

3. Portfolio shift becomes mandatory once HCV stops funding growth
   Gilead’s later-stage allocation emphasis moved away from HCV as it ceased being a primary growth driver, while other franchises and pipeline opportunities took center stage (source: business overview in annual reporting) [2], [3].

Market model summary: what drove Harvoni’s revenue trajectory?

Launch-led growth (2014-2015)

• High clinical performance and broad genotype coverage supported rapid adoption (regulatory context at launch) [1].

Mature peak (2016-2017)

• Stabilization across major payers and sustained uptake among diagnosed patients.

Erosion phase (2018 onward)

• Competitive DAA expansion plus generic pricing pressure
• Category demand compression from curing
• Payer net price optimization and utilization controls

This is consistent with how Gilead has described the HCV portfolio’s evolution from growth to mature decline in its public reporting (source: annual reporting business discussions around HCV performance) [2], [3].

---

Key Takeaways

• Harvoni launched in 2014 and delivered rapid early uptake in the DAA category, supported by regulator-approved clinical use (FDA approval package) [1].
• Its market dynamics followed HCV category maturity: front-loaded adoption, then sustained revenue erosion driven by competition, payer net pricing pressure, and shrinking treatable demand [2], [3].
• Gilead shifted corporate and capital emphasis away from HCV as the franchise matured and declined, reducing the likelihood of renewed growth without major new differentiation (annual reporting) [2], [3].
• For business planning, Harvoni is best modeled as a peak-then-decline platform common to DAA leaders: revenue durability depends on exclusivity and pricing power, not clinical dominance alone.

---

FAQs

1) What is Harvoni’s drug composition?

Harvoni is a fixed-dose combination of sofosbuvir and ledipasvir used to treat chronic hepatitis C virus infection (FDA approval package) [1].

2) Why did Harvoni sales decline after its early peak?

Sales declined due to HCV category maturation (fewer remaining eligible patients) and pricing erosion from competition and generic substitution, reflected in Gilead’s HCV segment narrative over time [2], [3].

3) How do payer dynamics influence Harvoni’s commercial outlook?

Once multiple DAA regimens deliver high cure rates, payers select based on net cost and access rules, compressing brand pricing and reducing volume for higher-priced options (captured in HCV business evolution described by Gilead) [2], [3].

4) What did Harvoni’s decline mean for Gilead’s broader strategy?

Gilead increased focus on other franchise growth and pipeline priorities as HCV stopped behaving like a growth engine, consistent with its annual business positioning [2], [3].

5) Is Harvoni still used clinically?

Harvoni remains an approved therapy for certain HCV treatment scenarios, but its commercial significance declines as market access favors newer or lower-cost regimens (FDA approval framework and Gilead’s HCV maturity reporting) [1], [2], [3].

---

References (APA)

[1] U.S. Food and Drug Administration. (2014). Drug Approval Package: Harvoni (sofosbuvir/ledipasvir). FDA.
[2] Gilead Sciences, Inc. (2024). Form 10-K: Business and financial review (HCV segment and product discussion). U.S. Securities and Exchange Commission.
[3] Gilead Sciences, Inc. (2023). Form 10-K: Business and financial review (HCV segment and product discussion). U.S. Securities and Exchange Commission.